English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

of results Median baseline characteristics were a patient age of 42 years, male gender (n = 139; 80.4%) and 10.1 years from first HIV-positive test. 158 patients were ART-experienced and received a boosted double PI regimen due to previous RTI-resistance and/or toxicity. Among these, 68 patients previously had a structured treatment interruption and 90 patients have been treated with a PI-sparing ART regimen; 15 patients were ART-naive. Differences for metabolic parameters between groups were not significant. Fiftyeight out of 173 patients received a lipid-lowering agent (LLA) (LOPSAQ n = 42, ATSAQ n = 11, FOSAQ n = 5) and seven (4%) were initiated on a new LLA during the study. Total cholesterol significantly increased over 48 weeks for all groups: 166 mg/dL to 213 mg/dL (LOPSAQ), 168 mg/ dL to 216 mg/dL (ATSAQ) and 161 mg/dl to 235 mg/dl (FOSAQ) after 48 weeks (for all, p < 0.01; ITT-analysis), whereas median triglyceride levels significantly increased only for the LOPSAQ-group (195 mg/dl to 283 mg/dl; p < 0.01), but not for the other two groups (ATSAQ: 161 mg/ dL to 202 mg/dL, p = 0.2; FOSAQ: 130 mg/dl to 220 mg/ dl, p = 0.6). HDLand LDL-cholesterol increased non-significantly in all groups. See Figure 1.

Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors